Bristol-Myers Squibb has been granted a patent for Mer-Ax1 inhibitors, which are compounds designed to treat proliferative disorders and dysregulated apoptosis, including cancer. The patent includes pharmaceutical compositions and methods for utilizing these compounds in treatment. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of June 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12037323B2 encompasses a series of claims related to specific chemical compounds, particularly those characterized by a complex molecular structure involving tetrahydropyrimidine derivatives. The primary claim outlines a compound defined by a specific formula, with subsequent claims elaborating on variations and specific configurations of this compound. Notably, claim 8 lists a range of compounds that include various substitutions and modifications, such as different pyridine derivatives and functional groups, which may enhance their therapeutic properties. These compounds are further described as potentially existing in pharmaceutically acceptable salt forms.
Additionally, the patent claims the use of these compounds in pharmaceutical compositions, as stated in claim 9, which may include various carriers, diluents, or excipients to facilitate their administration. Claim 10 specifies the therapeutic application of these compounds in treating various types of cancer, including small cell lung cancer, non-small cell lung cancer, and several others. This highlights the potential utility of the patented compounds in oncology, suggesting a targeted approach to cancer treatment through the use of these specific chemical entities.
To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
